logo
Flu's deadly toll rises in Michigan as 2 kids die in Kent County, 1 in Macomb County

Flu's deadly toll rises in Michigan as 2 kids die in Kent County, 1 in Macomb County

Yahoo27-02-2025

The deaths of three Michigan children from the flu were announced Thursday — bringing the grim tally statewide to five this year, state and local health officials told the Free Press.
Two of the most recent deaths occurred Kent County and the other was reported in Macomb County.
"I can confirm that there has been a pediatric flu-related death in Macomb County. We will not be releasing any further information on this unfortunate loss," said Andrew Cox, director/health officer of Macomb County Health and Community Services, in an emailed statement to the Free Press.
Neither the Michigan Department of Health and Human Services nor Cox would answer questions about when the child died, the age of the child, what strain of flu virus sickened the child, or whether the child had been hospitalized or received the seasonal flu vaccine.
In Kent County, Health Officer Dr. Adam London issued the following statement: 'We are deeply saddened by the loss of these young lives to influenza. This is a heartbreaking reminder that while the flu can be mild for some, it poses serious health risks for others. We encourage anyone who has not received a flu shot this season to consider doing so as soon as possible to protect our community and our children."
A spokesperson from Kent County did not immediately respond to a phone call or text message from the Free Press seeking information about when the children died, what type of flu virus they had, and whether they were vaccinated. Laina Stebbins, a spokesperson for the state health department, said only that they "are not sharing any further details."
The state health department reported the first two Michigan pediatric flu deaths of the season — in Wayne and Genesee counties — on Feb. 14 . Both of those children had the H1N1 type of influenza A, according to the state health department.
Their deaths come as flu activity surges in Michigan, putting pressure on hospital emergency departments. Corewell Health urged metro Detroiters earlier this month to carefully consider other options before seeking care at its hospitals, which have been strained by the rising number of people with flu, COVID-19 and RSV.
State influenza surveillance data shows that the spread of flu-like illnesses were at the highest level reportable — "very high" — in the week ending Feb. 15, with H1N1 and H3N2 types of influenza A causing the most infections.
In the last week alone, nearly 3,000 Michiganders were hospitalized with flu, according to the state dashboard. And among children, 9.7% of pediatric hospital emergency department visits were associated with flu, RSV or COVID-19 in the week ending Feb. 22. Of them, flu made up the lion's share, accounting for 7.9% of the hospital emergency visits among kids.
More: MDHHS: 2 Michigan children die from flu as hospitalizations climb
More: Michigan flu, RSV, COVID surges wreak 'havoc' in Corewell emergency departments
Statewide, seasonal flu vaccination rates are lower than they've been in the last several years. As of Feb. 22, just 24.7% of Michiganders had received the seasonal flu vaccine, according to the Michigan Seasonal Respiratory Viruses Dashboard.
When the first two Michigan children died, Dr. Natasha Bagdasarian, the state's chief medical executive, issued the following statement, reminding people that it's not too late to get the vaccine:
'We are heartbroken for the families who have experienced this loss. Last season, influenza claimed the lives of nearly 200 children across the United States. Influenza rates are currently very high, and if you did not receive a flu vaccine last fall, it is not too late to get one. It can still prevent the severe complications of influenza, including hospitalization and death.'
State health leaders recommend that everyone older than 6 months, including people who are pregnant, should get a seasonal flu vaccine. Additionally, when people get sick, it's important to get treatment early, they say, when antiviral medicine can limit the severity of illness and prevent dangerous complications.
Nationally, at least 86 children have died from flu so far this season, according to the U.S. Centers for Disease Control and Prevention.
There were eight pediatric flu deaths reported in Michigan during the 2023-24 season and eight in the 2022-23 season as well, Stebbins said.
(This story was updated with additional information.)
Contact Kristen Shamus: kshamus@freepress.com. Subscribe to the Detroit Free Press.
This article originally appeared on Detroit Free Press: Flu death toll rises to 5 in Michigan as 3 more children die

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Participants in program for elderly to rally in Lansing against Medicaid cuts
Participants in program for elderly to rally in Lansing against Medicaid cuts

Yahoo

time8 hours ago

  • Yahoo

Participants in program for elderly to rally in Lansing against Medicaid cuts

GRAND RAPIDS, Mich. (WOOD) — Potential Medicaid cuts in Congress could impact millions nationwide, including thousands in West Michigan. Advocates: Medicaid 'not a luxury,' lawmakers need plan for fallout At least 200 participants in the Program of All-Inclusive Care for the Elderly, or PACE, are visiting Lansing on Tuesday to urge state lawmakers to protect the program. PACE helps low-income seniors remain in their homes through care funded by Medicaid and Medicare. Sarah Milanowski, enrollment manager at LifeCircles PACE, said the issue affects both state and federal decision-makers. 'Medicaid is a state-administered program that has a portion of its funds from the federal government, and then the state matches funds,' she explained. 'So, as our local lawmakers are planning for their budget into the future, they are trying to hedge their bets about what might or might not be happening in Washington, D.C.' Republicans look for reset on Trump's 'big, beautiful bill' More than 2.6 million Michigan residents rely on Medicaid, according to the Michigan Department of Health and Human Services. That includes the 7,000 who use PACE services for medical care, transportation, prescriptions and more. PACE advocates are scheduled to meet with lawmakers starting at 9:30 a.m. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

New Covid-19 variant being monitored, but no resurgence of cases
New Covid-19 variant being monitored, but no resurgence of cases

News24

time9 hours ago

  • News24

New Covid-19 variant being monitored, but no resurgence of cases

Authorities are monitoring a new Covid-19 variant. However, this has not resulted in a resurgence of cases in South Africa. South Africa has also seen a seasonal increase in influenza. Health Minister Aaron Motsoaledi said South Africa is monitoring a new Covid-19 variant, but has not seen a resurgence in cases. Motsoaledi said that the new variant, known as Nimbus or NB.1.8.1, has been linked to a resurgence of cases in parts of Asia. 'The World Health Organisation (WHO) has designated this a variant under monitoring due to its growing presence,' he added. Speaking at the G20 Health Working Group Meeting on Tuesday, Motsoaledi said that South Africa continues to have robust surveillance systems in place. 'Our National Institute for Communicable Diseases (NICD) manages a comprehensive Sentinel Surveillance programme that systematically tests for key respiratory viruses, including SARS-CoV-2, influenza, and RSV. Currently, our data shows very low SARS-CoV-2 activity,' Motsoaledi said. READ | Trying to keep colds and flu's at bay this winter? Here's what you need in your kit He added that while there had been a seasonal increase in influenza, his department was 'well prepared to manage this' and that Covid-19 vaccinations should still prove effective. 'Crucially, the new variant remains a descendant of the Omicron lineage,' he said. This means that current recommendations for updated SARS-CoV-2 vaccines are still effective. Therefore, at this stage, no specific new public health actions are required from the public. 'We continue to advocate for maintaining good hygiene practices – such as handwashing, covering coughs, and staying home when unwell. These simple measures are effective in reducing the spread of all respiratory illnesses. We will continue to monitor the situation closely through our established networks and will report any significant changes.' A circular from the WHO shows that there has been a slight increase in the spread of Covid-19 in some regions due to the new variant. The WHO is closely observing the new variant and said that, while its unique mutations may slightly impact its contagiousness, current Covid-19 vaccines were still expected to provide strong protection. The WHO said there was no evidence that this variant caused more severe illnesses than previous ones.

Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments
Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments

Yahoo

time10 hours ago

  • Yahoo

Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments

Global Influenza Market to Hit USD 12.8 Billion by 2029: A Comprehensive AnalysisThe global influenza market, valued at USD 9 billion in 2024, is anticipated to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029. This growth is driven by the vaccine segment, the most effective preventive measure against influenza's severe effects. The report offers a thorough examination of market trends, including vaccines, diagnostics, and therapeutics, with insights into regional dynamics and competitive landscapes. Key players such as Danaher Corp., Sanofi, and Abbott are highlighted, alongside detailed analyses using Porter's Five Forces and PESTLE models. SEO keywords include global influenza market, influenza vaccines, diagnostics, and market growth. Influenza Market Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Influenza Market 2025" report has been added to Influenza Market was valued at USD 9 Billion in 2024, and is projected to reach USD 12.8 Billion by 2029, rising at a CAGR of 7.2%. The vaccines segment dominated the global influenza market in 2023. Because influenza vaccines are the most effective method for lowering the risk of contracting influenza and suffering its subsequent effects, the market for this segment is growing. Influenza comes in four varieties: A, B, C and D. Seasonal epidemics are caused by the infectious influenza A and B viruses. Most people recover from fever and other symptoms within a week without medical intervention. Nevertheless, influenza can result in fatalities or severe illness, particularly in high-risk populations. Seasonal influenza spreads quickly and easily in crowded places like schools and nursing homes, so receiving a vaccination as soon as possible is critical. Based on vaccine type, the segment is further subdivided into inactivated and liveattenuated market for influenza diagnostics has been segmented into rapid tests and conventional lab tests based on diagnostic type. Increased R&D efforts are being made to detect and diagnose influenza more accurately due to its increasing global prevalence. Research is focusing on developing quicker and more precise diagnostic tools for influenza viruses, which will expand the drugs approved for influenza treatments are discussed in the therapeutic segment. These medications may lessen the likelihood of complications, lessen the severity of symptoms and shorten the course of the illness. These drugs include oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) and baloxavir marboxil (Xofluza).Report ScopeThis report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions - North America, Europe and Asia-Pacific - and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through report includes: 55 data tables and 70 additional tables An updated overview and in-depth analysis of the global influenza market Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029 Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV) Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors Insight into the influenza industry structure, government regulations, and key development issues Analysis of the key patent grants and IP aspects A discussion of the industry's ESG challenges and practices of the industry Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott Key Attributes: Report Attribute Details No. of Pages 188 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $9 Billion Forecasted Market Value (USD) by 2029 $12.8 Billion Compound Annual Growth Rate 7.2% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Pandemic Scenario Porter's Five Forces Analysis in the Influenza Vaccines Market Supply Chain Analysis Vaccine Development Vaccine Manufacturing Storage and Inventory Management Distribution Administration and Immunization Macroeconomic Factors Analysis Impact of U.S.-China Trade War Global Economic Growth Demographic Trends Public Health Crises and Pandemics Chapter 3 Market Dynamics Market Dynamics Key Takeaways Market Drivers Development of Rapid Tests and Molecular Technologies Government Support and Funding for Novel Therapies and Diagnosis Rising Public Awareness About Flu Vaccines Market Restraints Therapeutic Market Dominated by Limited Suppliers High Cost Associated with Storage and Supply of Flu Vaccines Market Opportunities Robust Pipeline of Influenza Vaccines Demand for Improved Prevention, Treatment and Vaccine Accessibility Chapter 4 Regulatory Landscape Overview Regulatory Aspects of Influenza Vaccines Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season Influenza Vaccines Approved by EMA Regulatory Scenario of Influenza Drugs Approval Process of Influenza Detection Kit Sensitivity Specificity Chapter 5 Emerging Trends and Pipeline Analysis Overview Advance in Influenza Diagnosis SHINE Technology Electrochemical Biosensors Wearable Lab-on-a-Chip Devices Quantum Dots and Fluorescent Nanoparticles Role of AI in Influenza Diagnosis Emerging Technologies in Influenza Vaccines Universal Influenza Vaccine mRNA-based Influenza Vaccines Nanotechnology-based Vaccines Patch-based Vaccines Advances in Influenza Therapeutics Nanoparticle-based Therapies Potential Drug Agents in Clinical Trials Patent Analysis Key Takeaways Chapter 6 Market Segmentation Analysis Segmentation Breakdown Global Influenza Market by Product Segment Influenza Diagnostics Influenza Vaccines Influenza Therapeutics Geographic Breakdown Key Takeaways North America Europe Asia-Pacific Rest of World Chapter 7 Competitive Intelligence Company Share Analysis of the Influenza Vaccines Market Company Share Analysis of Influenza Diagnostics Market Company Share Analysis of Influenza Therapeutics Market Venture Fundings and Investments Landscape Key Developments in Market Chapter 8 Sustainability in Influenza Market: ESG Perspective Overview ESG Risk Ratings Conclusion Chapter 9 AppendixCompanies Featured Abbott AstraZeneca BD Biocryst Pharmaceuticals Inc. CSL Daiichi Sankyo Co. Ltd. Danaher Corp. F. Hoffmann-La Roche Ltd. GSK PLC Hologic Inc. Quidelortho Corp. Sanofi Sekisui Diagnostics Thermo Fisher Scientific Inc. Viatris Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Influenza Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store